Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
- Conditions
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Atrial Fibrillation Network
- Target Recruit Count
- 108
- Registration Number
- NCT02933697
- Locations
- 🇩🇪
Universitätsklinikum Münster, Münster, Germany
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT02912234
- Locations
- 🇺🇸
Ppd Development, Llc, Austin, Texas, United States
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Sanford Health
- Target Recruit Count
- 56
- Registration Number
- NCT02889562
- Locations
- 🇺🇸
Sanford Health, Fargo, North Dakota, United States
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
- Conditions
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 19
- Registration Number
- NCT02829957
- Locations
- 🇺🇸
Eskenazi Health System, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28000
- Registration Number
- NCT02792335
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14201
- Registration Number
- NCT02769078
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 321182
- Registration Number
- NCT02754154
A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 2
- Registration Number
- NCT02749617
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 811
- Registration Number
- NCT02744092
- Locations
- 🇺🇸
Washington Hospital, Fremont, California, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸Saint Joseph's Medical Center, Stockton, California, United States
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
- Conditions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2081
- Registration Number
- NCT02714855
- Locations
- 🇫🇷
Local Institution, Fontaine Les Dijon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.